Trial Watch: Toll-like receptor agonists in cancer immunotherapy Journal Article

   


Authors: Smith, M.; García-Martínez, E.; Pitter, M. R.; Fucikova, J.; Spisek, R.; Zitvogel, L.; Kroemer, G.; Galluzzi, L.
Article Title: Trial Watch: Toll-like receptor agonists in cancer immunotherapy
Abstract: Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy. © 2018, © 2018 Taylor & Francis Group, LLC.
Keywords: imiquimod; motolimod; sd-101; ampligen®; bacillus calmette-guérin; hiltonol®
Journal Title: OncoImmunology
Volume: 7
Issue: 12
ISSN: 2162-4011
Publisher: Landes Bioscience  
Date Published: 2018-12-01
Start Page: e1526250
Language: English
DOI: 10.1080/2162402x.2018.1526250
PROVIDER: scopus
PMCID: PMC6279325
PUBMED: 30524908
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058033462&doi=10.1080%2f2162402X.2018.1526250&partnerID=40&md5=760026aab399ef58db150ff9a4d33062
Notes: OncoImmunology -- Export Date: 2 January 2019 -- Review -- Source: Scopus C7 - e1526250
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Melody Smith
    33 Smith
  2. Michael Reginald Pitter
    1 Pitter
Related MSK Work